Accustem Sciences Files Q3 2024 10-Q

TL;DR

Accustem Sciences filed its Q3 2024 10-Q. Check financials.

AI Summary

Accustem Sciences Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Specific financial details and operational updates for this period are detailed within the report.

Why It Matters

This filing provides investors with the latest financial performance and operational status of Accustem Sciences Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains financial data and operational updates which can indicate varying levels of risk for investors.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Covers the third quarter and nine months of fiscal year 2024.)
• 2024-11-18 — Filing Date (Date the 10-Q was submitted to the SEC.)

Key Players & Entities

• Accustem Sciences Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of the reporting period
• 2024-11-18 (date) — Filing date
• 5 PENN PLAZA, 19TH FLOOR #1954 NEW YORK NY 10001 (address) — Business and mailing address

FAQ

Key Financial Figures

• $1.076247 — m EUROS to USD using exchange rate of 1:$1.076247 ) 50,000 ($ 53,812 ) within 30 days

Filing Documents

• form10-q.htm (10-Q) — 831KB
• ex31-1.htm (EX-31.1) — 14KB
• ex31-2.htm (EX-31.2) — 14KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-046438.txt ( ) — 4135KB
• acut-20240930.xsd (EX-101.SCH) — 26KB
• acut-20240930_cal.xml (EX-101.CAL) — 33KB
• acut-20240930_def.xml (EX-101.DEF) — 96KB
• acut-20240930_lab.xml (EX-101.LAB) — 235KB
• acut-20240930_pre.xml (EX-101.PRE) — 176KB
• form10-q_htm.xml (XML) — 740KB

- FINANCIAL INFORMATION

PART I- FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 1 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 2 Unaudited Condensed Statements of Changes in Stockholders' Deficit for the Three and Nine Months Ended September 30, 2024 and 2023 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

- OTHER INFORMATION

PART II - OTHER INFORMATION 20 Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21

SIGNATURES

SIGNATURES 22 i PART I - FINANCIAL INFORMATION Item 1. Financial Statements The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information which are the accounting principles that are generally accepted in the United States of America and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations and cash flows of the Company for the interim periods presented. The results for the period ended September 30, 2024 are not necessarily indicative of the results of operations for the full year. These financial statements and related notes should be read in conjunction with the consolidated financial statements and notes thereto included in our audited consolidated financial statements for the fiscal years December 31, 2023 and 2022 included in our annual report on Form 10-K filed with the US. Securities and Exchange Commission (the "SEC") on March 22, 2024. ACCUSTEM SCIENCES INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED) September 30, 2024 December 31, 2023 ASSETS Current Assets Cash $ 37,080 $ 21,481 Prepaid expenses 65,414 108,368 Other Current Assets - Total Current Assets 102,494 129,849 Equipment, net 1,325 4,048 TOTAL ASSETS $ 103,819 $ 133,897 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $ 790,241 $ 578,378 Related party payable 2,285,562 1,454,986 Accrued expenses 164,053 156,434 Note Payable 57,597 55,679 Total Current Liabilities 3,297,453 2,245,

View Full Filing

View this 10-Q filing on SEC EDGAR